A company named AbbVie is doing pretty well. People who know a lot about companies (analysts) think it might go up in the future, so they buy options for it. An option is like a bet: you pay a little bit of money now, and if something happens later, you win a lot of money. But if that thing doesn't happen, you lose the money you paid.

There are different types of options: some are bullish (that means people think the stock will go up) and some are bearish (that means people think the stock will go down). The bullish people bet that AbbVie's stock will go up to $195 or even more in the next 3 months. The bearish people think it will go down to $150 or less.

A lot of people are making these bets right now. Some of them are buying options that say AbbVie's stock will go up. Some are buying options that say it will go down. No one knows for sure what will happen, but it's interesting to see what all these big-money people are betting on! Read from source...

1. Trying to label AbbVie's options trading as bullish or bearish, without any supporting evidence or context, is a classic example of inconsistency. There's no information on why these big trades occurred, and it's unfair to label them based on assumptions.

2. The article contains emotional language such as "heavyweight investors", "out of the ordinary", and "something big is about to happen". This kind of language is not objective or neutral and introduces bias into the discussion.

3. The analysis seems to be based more on speculation than on solid facts. The argument that big money traders are moving in a particular direction is not supported by any data or research.

4. The article assumes that options traders are always correct, which is not true. Options traders can be wrong just like any other investor.

5. The author seems to be encouraging people to follow the options trading activity of big money traders, which is a AIgerous move. This kind of trading strategy can lead to significant losses.

In conclusion, the article is not based on objective analysis and is full of inconsistencies and biases. Investors should not rely on this kind of information when making investment decisions.

To be fair, the author did disclose that this information comes from Benzinga, which is a reliable source. However, the way this information is presented and interpreted is not objective or balanced.

Negative

Psychedelics Prohibited and Regulated Products Score -87.5

Semiconductor Companies Score -85.71

Market ETFs Score -85.4

Diamond Corp Score -85.36

Aerospace and Defense Companies Score -85.33

### ◀️ WHAT'S HAPPENING

- AbbVie ABBV reports Q2 EPS of $3.62, beating the Zacks Consensus Estimate of $3.58.
- The EPS result was 14.6% higher than the same quarter one year ago.
- The company reports net sales of $14.62 billion, beating the Zacks Consensus Estimate of $14.41 billion.

### ✏️ ANALYSTS' COMMENTS

- Stifel analyst Annabel Samimy maintains a Hold rating on AbbVie and raises the price target from $145 to $150. The analyst highlights the company's guidance update, "we believe the company's guidance increase indicates a positive turn in near-term quarters, particularly 2H22."

- Morgan Stanley analyst Matthew Harrison maintains an Overweight rating and raises the price target from $177 to $190. The analyst notes, "we continue to view ABBV as the highest quality and most underappreciated large-cap pharma stock."

- Mizuho analyst Vamil Divan maintains a Buy rating and raises the price target from $185 to $200. The analyst comments, "ABBV continues to build momentum with its diverse pipeline, delivering record revenues and EPS in Q2. We view the stock as attractively valued with a self-sustaining growth trajectory and healthy capital allocation strategy."

- Wedbush analyst David Nierengarten maintains an Outperform rating and raises the price target from $180 to $200. The analyst comments, "we continue to view AbbVie as a compelling value within large-cap biopharma. The story continues to evolve with expanding product portfolios across both immunology and oncology."

- Deutsche Bank analyst Richard Vosser maintains a Buy rating and raises the price target from $160 to $170. The analyst notes, "we believe a combination of product launches, ex-Humira growth and a robust pipeline set the stage for durable earnings growth over the next several years."

- Credit Suisse analyst Martin Austenburg maintains a Neutral rating and raises the price target from $160 to

Are you looking for a trusted and reliable platform that can help you make smart and informed investment decisions? AI provides a comprehensive platform that offers research-based recommendations to help you grow your wealth. In this article, we will explore the various benefits of using AI, the different investment options available, and how it can help you make informed decisions.

Benefits of Using AI:

1. Comprehensive Research-Based Recommendations: AI provides you with comprehensive research-based recommendations that can help you make informed investment decisions. The platform analyzes various market trends and patterns to provide you with accurate and reliable recommendations.

2. Diverse Investment Options: AI offers a wide range of investment options, including stocks, bonds, mutual funds, ETFs, and more. This allows you to diversify your portfolio and reduce the risk of investing in a single asset class.

3. Risk Management: AI also provides risk management tools that can help you manage the risks associated with investing. The platform provides you with various risk management tools that can help you minimize your exposure to market volatility and protect your investments.

4. User-Friendly Interface: AI has a user-friendly interface that makes it easy for you to navigate through the platform. The platform is designed to be intuitive and easy to use, even for people who are new to investing.

5. Customer Support: AI offers exceptional customer support to help you with any questions or concerns you may have. The platform has a dedicated customer support team that is available 24/7 to help you with any issues you may encounter.

Investment Options Available on AI:

1. Stocks: AI offers a wide range of stocks from various industries and sectors. The platform provides you with detailed information on each stock, including its performance history, financial statements, and more.

2. Bonds: AI also offers various bond options, including government bonds, municipal bonds, and corporate bonds. The platform provides you with detailed information on each bond, including its interest rate, maturity date, and more.

3. Mutual Funds: AI offers a wide range of mutual funds, including index funds, sector funds, and more. The platform provides you with detailed information on each mutual fund, including its performance history, expense ratio, and more.

4. ETFs: AI also offers various ETF options, including index ETFs, sector ETFs, and more. The platform provides you with detailed information on each ETF, including its performance history, expense ratio, and more.

How AI Can Help You Make Informed Decisions:

1. Detailed Market Research: AI provides you with detailed market research that can help you make informed investment decisions. The platform analyzes various